Sichenzia Ross Ference LLP Represents Biotricity, Inc. in $2 Million Sale of Series B Preferred Stock

Press Release – New York, NY – September 21, 2023 – Sichenzia Ross Ference LLP announced today that it represented Biotricity, Inc. (NASDAQ: “BTCY”) (the “Company”), a medical diagnostic and consumer healthcare technology company, in a $2 Million sale of Series B Preferred Stock. 

The Company entered into a security purchase agreement with an institutional investor for the issuance and sale of 220 shares of the Company’s newly designated Series B Convertible Preferred Stock, $0.001 par value (the “Series B Preferred Stock”), at a purchase price of $9,090.91 per share of Preferred Stock, or gross proceeds of $2,000,000.

Shares of Series B Preferred Stock and shares of Common Stock of the Company that are issuable upon conversion of, or as dividends on, the Series B Preferred Stock were offered, and will be issued, pursuant to the Prospectus Supplement, filed on September 19, 2023, to the Prospectus included in the Company’s Registration Statement on Form S-3 (Registration No. 333-255544) filed with the Securities and Exchange Commission on April 27, 2021, and declared effective May 4, 2021.

The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Marcelle Balcombe, and Jeff Cahlon and associate Mayank Pradhan.